Avid Bioservices (CDMO) Misses Q2 EPS by 9c, adjusts guidance

Avid Bioservices (NASDAQ: CDMO) reported Q2 EPS of ($0.15), $0.09 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $25.4 million versus the consensus estimate of $33.22 million.

GUIDANCE:

Avid Bioservices sees FY2024 revenue of $137-147 million, versus the consensus of $154.1 million.

For earnings history and earnings-related data on Avid Bioservices (CDMO) click here.

You May Also Be Interested In

• John Wiley & Sons, Inc. (WLY) Tops Q1 EPS by 4c ; Offers Guidance
• Asana, Inc. (ASAN) Tops Q2 EPS by 1c; offers guidance
• lululemon athletica (LULU) Tops Q2 EPS by $1.10, Cuts Guidance